Sort
4,870 grants matching “glp 1”
Development and evaluation of novel high-density intracortical microelectrode arrays for clinical applications
$1,488,420Matthew R Angle · Paradromics, Inc. · R44 · FY2021 · MH
Development of novel NLRP3 inflammasome inhibitors for intervening in Alzheimer's disease
$1,482,927Shijun Zhang · Virginia Commonwealth University · U01 · FY2025 · AG
Extended-release injectable gel for multi-day treatment of postoperative pain
$1,479,276Derek James Overstreet · Sonoran Biosciences, Inc. · R44 · FY2025 · GM
Optimization of Iron Chelator Delivery System
$1,475,189Judith K Gwathmey · Gwathmey, Inc. · R44 · FY2009 · HL
Completion of IND-package for a novel, non-narcotic painkiller
$1,474,091Ajay S Yekkirala · Blue Therapeutics, Inc. · R44 · FY2019 · DA
Development of a Next Generation Anthrax Vaccine, AV7909
$1,471,421Sukjoon Park · Emergent Product Development Gaithersbur · U01 · FY2008 · AI
Structural Analysis Of Candidate Genes For Type 2 Diabetes and Obesity
$1,471,386Leslie J Baier · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2019 · DK
Preclinical Development of a Selective Suppressor of Neuroinflammation for MCI/AD
$1,468,850Linda J Van Eldik · University Of Kentucky · U01 · FY2017 · AG
Glycemia Reduction Approaches in Diabetes: A comparative effectiveness study
$1,460,731John M Lachin · George Washington University · U01 · FY2016 · DK
Translating a CSF delivered AAV9-SMN for treatment of Spinal Muscular Atrophy
$1,459,274Brian K Kaspar · Research Inst Nationwide Children'S Hosp · U01 · FY2013 · NS
National Islet Cell Consortium Coordinating Center
$1,455,005Joyce Carol Niland · Beckman Research Institute/City Of Hope · U42 · FY2006 · RR
Development and Commercialization of a Tau Oligomer Inhibitor for AD/RD
$1,452,237James G. Moe · Oligomerix, Inc · R44 · FY2020 · AG
Developing autologous iPSC-RPE based IND for AMD patients
$1,450,454Kapil Bharti · National Eye Institute · ZIA · FY2019 · EY
Development of N-tert-(Butyl)hydroxylamine (NtBuHA) as a therapeutic agent for treating Infantile Neuronal Ceroid Lipofuscinosis (INCL)
$1,449,910Daniel Chelsky · Circumvent Pharmaceuticals, Inc. · R44 · FY2022 · NS
Developing autologous iPSC-RPE based IND for AMD patients
$1,448,812Kapil Bharti · National Eye Institute · ZIA · FY2014 · EY
Treatment of pulmonary fibrosis with inhibitors of integrin alphavbeta1.
$1,446,327Dean Sheppard · University Of California, San Francisco · UH3 · FY2016 · HL
Experimental Animal Models of TB: Chemotherapeutics and Imaging
$1,444,144Clifton Barry · National Institute Of Allergy And Infectious Diseases · ZIA · FY2019 · AI
Development of N-tert-(Butyl)hydroxylamine (NtBuHA) as a therapeutic agent for treating Infantile Neuronal Ceroid Lipofuscinosis (INCL)
$1,441,757Devin Thomas Wiley · Circumvent Pharmaceuticals, Inc. · R44 · FY2021 · NS
Clinical Evaluation of an Innovative PSMA-targeted Radiotherapy, CTT1403, in Prostate Cancer
$1,441,580Beatrice Langton-Webster · Cancer Targeted Technology, Llc · R44 · FY2020 · CA
Gene Therapy for Brain Tumors
$1,440,815Fred H Hochberg · Massachusetts General Hospital · P01 · FY2010 · CA
Development and evaluation of novel high-density intracortical microelectrode arrays for clinical applications
$1,433,024Matthew R Angle · Paradromics, Inc. · R44 · FY2022 · MH
Device for Treatment of Cardiac No-Option Patients
$1,432,551Mengjun Wang · 3dt Holdings, Llc · R44 · FY2018 · HL
Clinical Psychoneuroendocrinology and Neuropsychopharmacology (CPN)
$1,432,347Lorenzo Leggio · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2014 · AA
Oxadiazole Inhibitors of Non-Stop Ribosome Rescue to treat MDR Neisseria gonorrhoeae
$1,432,109Zachary David Aron · Microbiotix, Inc · R01 · FY2017 · AI
Development of KCC2 Neuromodulators to Treat Paralysis After Spinal Cord Injury.
$1,426,925Joanna Stanicka · Axonis Therapeutics, Inc. · R44 · FY2023 · NS